A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild SARS-CoV-2 Infection
Latest Information Update: 22 Apr 2022
At a glance
- Drugs RP 7214 (Primary) ; Antivirals
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors Rhizen Pharmaceuticals
- 20 Apr 2022 Status changed from recruiting to completed.
- 01 Feb 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Feb 2022.
- 21 Sep 2021 According to the Rhizen Pharmaceuticals media release, first patient has been dosed in this trial.